Spots Global Cancer Trial Database for A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
Official Title: A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients With Relapsed/Refractory Multiple Myeloma
Study ID: NCT05535244
Conditions
Study Description
Brief Summary: This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic - Arizona, Phoenix, Arizona, United States
University of Colorado, Aurora, Colorado, United States
Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Icahn School of Medicine at Mount Sinai (ISMMS); The Derald H. Ruttenberg Treatment Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
Methodist Hospital, San Antonio, Texas, United States
Hunstman Cancer Institute, Salt Lake City, Utah, United States
Calvary Mater Newcastle; Hematology, Waratah, New South Wales, Australia
St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
UZ Leuven Gasthuisberg, Leuven, , Belgium
APHP - Hospital Saint Louis, Paris, , France
CHU de Poitiers - La Miletrie; Oncologie hematologique - Pole Regional de Cancerologie, Poitiers, , France
CAMPUS BENJAMIN FRANKLIN CharitéCentrum 14 Med.Klinik f.Hämatologie u.Onkologie, Berlin, , Germany
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, Hamburg, , Germany
Klinik der Uni zu Köln; Klinik für Innere Medizin, Köln, , Germany
Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II, Tübingen, , Germany
Universitätsklinikum Würzburg; Medizinische Klinik und Poliklinik II; Hämatologie / Onkologie, Würzburg, , Germany
Hadassah Ein Karem Hospital; Haematology, Jerusalem, , Israel
Sheba Medical Center; Tel Hashomer, Ramat Gan, , Israel
Sourasky Medical Centre, Tel-Aviv, , Israel
Policlinico S.Orsola-Malpighi;Istituto di Ematologia "Seragnoli", Bologna, Emilia-Romagna, Italy
ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, Italy
Fond. IRCCS Istituto Nazionale Tumori; S. C. Ematologia, Milano, Lombardia, Italy
A.O. Città della Salute e della Scienza D - Osp. S. Giov. Battista Molinette; Ematologia I, Torino, Piemonte, Italy
Clinica Universitaria de Navarra; Servicio de Hematologia, Pamplona, Navarra, Spain
Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, , Spain
Clinica Universidad de Navarra Madrid; Servicio de Hematología, Madrid, , Spain
Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, , Spain
Hospital Universitario la Fe; Servicio de Hematologia, Valencia, , Spain
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
